Scout Investments Inc. bought a new position in Medpace Holdings Inc (NASDAQ:MEDP) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 61,750 shares of the company’s stock, valued at approximately $3,268,000. Scout Investments Inc. owned approximately 0.17% of Medpace at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc raised its holdings in shares of Medpace by 63.6% in the 3rd quarter. Vanguard Group Inc now owns 2,897,702 shares of the company’s stock worth $173,601,000 after buying an additional 1,126,649 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Medpace by 63.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,897,702 shares of the company’s stock worth $173,601,000 after buying an additional 1,126,649 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Medpace by 42.1% in the 3rd quarter. BlackRock Inc. now owns 2,282,063 shares of the company’s stock worth $136,719,000 after buying an additional 676,396 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Medpace by 14.2% in the 3rd quarter. Acadian Asset Management LLC now owns 1,464,121 shares of the company’s stock worth $87,717,000 after buying an additional 182,588 shares in the last quarter. Finally, Laurion Capital Management LP raised its holdings in shares of Medpace by 63.1% in the 3rd quarter. Laurion Capital Management LP now owns 1,108,556 shares of the company’s stock worth $66,414,000 after buying an additional 428,785 shares in the last quarter. 67.54% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have recently issued reports on MEDP. ValuEngine raised Medpace from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research cut Medpace from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. BidaskClub cut Medpace from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 18th. Finally, SunTrust Banks raised Medpace from a “hold” rating to a “buy” rating and set a $63.00 target price for the company in a report on Wednesday, October 31st. They noted that the move was a valuation call. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $44.43.
Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Thursday, November 1st. The company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.04. Medpace had a return on equity of 15.86% and a net margin of 10.84%. The firm had revenue of $179.00 million during the quarter, compared to analysts’ expectations of $175.07 million. During the same period last year, the firm posted $0.40 EPS. The business’s revenue was up 44.4% on a year-over-year basis. As a group, equities research analysts expect that Medpace Holdings Inc will post 2.51 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Scout Investments Inc. Invests $3.27 Million in Medpace Holdings Inc (MEDP)” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2019/01/14/scout-investments-inc-invests-3-27-million-in-medpace-holdings-inc-medp.html.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Recommended Story: Hedge Funds Explained
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.